Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
CSPC Pharmaceutical Group (HK:1093)
:1093
1093 Stock Chart & Stats
Day’s Range― - ―
52-Week RangeHK$4.27 - HK$7.83
Previous CloseN/A
Volume61.16M
Average Volume (3M)60.61M
Market Cap
HK$55.66B
Enterprise ValueN/A
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)8.9
Beta1.00
Next Earnings
Mar 19, 2025EPS Estimate
0.13Last Dividend Ex-Date
Oct 31, 2024Dividend Yield6.25%
Share Statistics
EPS (TTM)0.54
Shares Outstanding11,543,702,000
10 Day Avg. Volume84,804,111
30 Day Avg. Volume60,609,493
Standard Deviation0.11
R-Squared0.16
Alpha-0.00068
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)2.85
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$4.82Price Target Upside-1.23% Downside
Rating ConsensusHold
Number of Analyst Covering2
---
CSPC Pharmaceutical Group News
PremiumCompany Announcements
CSPC Pharmaceutical Gains Approval for New Indication of Enyitan
PremiumCompany Announcements
CSPC Pharmaceutical’s SYH2059 Tablets Receives U.S. Clinical Trial Approval
PremiumCompany Announcements
CSPC Secures Clinical Trial Approval for Herpes Zoster Vaccine
PremiumCompany Announcements
CSPC Pharmaceutical Group Announces Change of Share Registrar
PremiumCompany Announcements
CSPC Innovation Reports Significant Profit Decline in 2024
PremiumCompany Announcements
CSPC Pharma’s New Cancer Drug Approved for U.S. Trials---
Bulls Say, Bears Say
Bulls Say
Growth PotentialInvestors are expected to gradually shift focus to new product sales ramp-up, for which a 52% CAGR is projected in the coming years.
Bears Say
Financial PerformanceManagement cited two forces behind the weak 2Q24 results: Underestimation of VBP price cut impact on Jinyouli and Duomeisu from 3+N regional VBP programs with price linkage being adopted province by province in 2024/25.
Market ConditionsGiven the lingering anti-corruption and VBP impacts for major products, downside risk to full-year earnings is now seen.
---
Options Prices
Currently, No data available
---
Ownership Overview
―
Insiders
3.51% Mutual Funds
― Other Institutional Investors
89.66% Public Companies and
Individual Investors
1093 FAQ
What was CSPC Pharmaceutical Group ’s price range in the past 12 months?
CSPC Pharmaceutical Group lowest stock price was HK$4.27 and its highest was HK$7.83 in the past 12 months.
What is CSPC Pharmaceutical Group ’s market cap?
CSPC Pharmaceutical Group ’s market cap is HK$55.66B.
When is CSPC Pharmaceutical Group ’s upcoming earnings report date?
CSPC Pharmaceutical Group ’s upcoming earnings report date is Mar 19, 2025 which is in 26 days.
How were CSPC Pharmaceutical Group ’s earnings last quarter?
CSPC Pharmaceutical Group released its earnings results on Nov 15, 2024. The company reported HK$0.066 earnings per share for the quarter, missing the consensus estimate of HK$0.11 by -HK$0.044.
Is CSPC Pharmaceutical Group overvalued?
According to Wall Street analysts CSPC Pharmaceutical Group ’s price is currently Overvalued.
Does CSPC Pharmaceutical Group pay dividends?
CSPC Pharmaceutical Group pays a Annually dividend of HK$0.159 which represents an annual dividend yield of 6.25%. See more information on CSPC Pharmaceutical Group dividends here
What is CSPC Pharmaceutical Group ’s EPS estimate?
CSPC Pharmaceutical Group ’s EPS estimate is 0.13.
How many shares outstanding does CSPC Pharmaceutical Group have?
CSPC Pharmaceutical Group has 11,543,702,000 shares outstanding.
What happened to CSPC Pharmaceutical Group ’s price movement after its last earnings report?
CSPC Pharmaceutical Group reported an EPS of HK$0.066 in its last earnings report, missing expectations of HK$0.11. Following the earnings report the stock price went down -1.156%.
Which hedge fund is a major shareholder of CSPC Pharmaceutical Group ?
Currently, no hedge funds are holding shares in HK:1093
---
CSPC Pharmaceutical Group Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
HK$4.82 (-1.23% Downside)
HK$4.82 (-1.23% Downside)
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-18.12%
12-Months-Change
Fundamentals
Return on Equity
17.87%
Trailing 12-Months
Asset Growth
9.64%
Trailing 12-Months
Company Description
CSPC Pharmaceutical Group
CSPC Pharmaceutical Group Ltd. is an investment holding company, which is engaged in the manufacturing and selling of pharmaceutical products. It operates through the following business segments: Finished Drugs, Antibiotics, Vitamin C, Caffeine and Others. The company was founded on August 21, 1997 and is headquartered in Hong Kong.
---
1093 Stock 12 Month Forecast
Average Price Target
HK$4.82
▼(-1.23% Downside)
Technical Analysis
Ping An Insurance Company of China
―
Sino Biopharmaceutical
―
China Medical System Holdings
―
Livzon Pharmaceutical Group
―
China Resources Pharmaceutical Group Ltd.
―
Best Analysts Covering 1093
1 Year
1 Year Success Rate
1/5 ratings generated profit
1 Year Average Return
-15.46%
reiterated a buy rating 4 months ago
Copying Zhijie Zhao's trades and holding each position for 1 Year would result in 20.00% of your transactions generating a profit, with an average return of -15.46% per trade.
---